MDGL Madrigal Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-09 16:00
Why MDGL matters now
Madrigal Pharmaceuticals, Inc. (MDGL) is a US stock in Healthcare. The latest InvestLog snapshot shows $560.01 with -0.95% on the session and $12.91B in market capitalization; recent performance reads 1-month -1.19% and YTD -13.15%.
The latest financial table shown here is Q1 2026, with revenue of $311.3M, net income of $-94.4M, and EPS of $-3.25. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.3%.
The latest indexable market news headline is "Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $579.00; recent insider activity includes BAKER BROS. ADVISORS LP filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
27.02
P/S
10.30
EV/EBITDA
-41.89
DCF Value
$2,867.98
FCF Yield
-2.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.1%
Operating Margin
-27.7%
Net Margin
-27.3%
ROE
-50.2%
ROA
-25.2%
ROIC
-35.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $311.3M | $-94.4M | $-3.25 |
| Q4 2025 | $321.1M | $-58.6M | $-2.57 |
| FY 2025 | $958.4M | $-288.3M | $-12.85 |
| Q3 2025 | $287.3M | $-114.2M | $-5.08 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$656.00
Target (Median)
$579.00
Target Range
$542.00 - $964.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-1.06
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.